Long-Term Impacts of Invasive Meningococcal Disease on Survivors and Their Caregivers in the United States and Canada
Authors:
- John B. GrimesJGJohn B. Grimes
- Liga BennettsLBLiga Bennetts
Open Access
- 8 July 2025
- journal article
- review article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (8) , 1577-1597
Abstract
Introduction Adolescents and young adults are among those most often impacted by invasive meningococcal disease (IMD), and survivors are often left with serious and permanent physical, neurological, psychological, or systemic complications. We conducted this targeted literature review with the primary goal of identifying evidence and evidence gaps relating to long-term health-related quality-of-life (HRQoL) and economic impacts for survivors who contracted IMD during adolescence or early adulthood and their caregivers. Methods We searched electronic databases and gray literature for studies assessing long-term clinical, HRQoL, and economic outcomes for patients who survived IMD in the US or Canada. Expert input provided by a survivor and patient advocate, as well as a pediatrician, was used to explore impacts and evidence gaps. Results Eleven studies met the prespecified inclusion criteria for this review. Seven studies from the US and four from Canada reported on long-term outcomes of interest, including ten studies reporting clinical sequelae experienced by IMD survivors, three reporting HRQoL/social impacts, five reporting healthcare resource utilization, and four reporting direct costs. Across seven studies, 10.6–41% of IMD survivors had ≥ 1 sequelae, with prominent examples including seizures, deafness or hearing loss, stroke, amputation, skin scarring, and renal dysfunction or failure. Qualitative interviews and questionnaires revealed that survivors face significant and persistent emotional distress and physical impairment that limit daily functioning and social activities. Healthcare resource use, including inpatient stays and specialist visits following IMD was high, leading to substantial healthcare costs, especially among survivors with sequelae. Expert input highlighted that much of the burden encountered by survivors is not included in the published literature, including the cumulative out-of-pocket and indirect costs of living with sequelae for decades and the extent of the physical, psychological, and social impacts. Conclusion While published evidence suggests that survivors with sequelae from IMD during adolescence or young adulthood have long-term and significant humanistic and economic impacts, considerable and important evidence gaps remain.Keywords
Funding Information
- Sanofi
This publication has 41 references indexed in Scilit:
- Meningococcal Vaccination in the United States: Past, Present, And FuturePediatric Drugs, 2025
- Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young AdultsJAMA Network Open, 2024
- Life After Invasive Meningococcal Disease: Insights from Survivors and Their CaregiversInfectious Diseases and Therapy, 2024
- Understanding the Sequelae of Invasive Meningococcal Disease in the United StatesInfectious Diseases and Therapy, 2024
- Invasive meningococcal disease in older adults: current perspectives and call for actionEuropean Geriatric Medicine, 2024
- Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United StatesJAMA Pediatrics, 2020
- Risk factors for meningococcal disease in children and adolescents: a systematic review and META-analysisEuropean Journal of Pediatrics, 2020
- An Overview of Neisseria meningitidis2019
- Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their CaregiversInfectious Diseases and Therapy, 2018
- Costs of Sequelae Associated with Invasive Meningococcal Disease: Findings from a US Managed Care PopulationHealth Outcomes Research in Medicine, 2011